It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out ...

In 2024, Eli Lilly's revenue increased by 32% year over year to $45 billion. The tirzepatide franchise contributed about $16.5 billion -- despite having been on the market for less than three years.

Eli Lilly remains a favorite among billionaires, ranking 11th in top stock picks. The pharmaceutical giant’s 2024 revenue ...

Eli Lilly and Company's latest 10-K report for the year ended December 31, 2024, reveals significant financial growth. The company reported a revenue of $45,042.7 million, marking a 32% increase from ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

On Feb. 27, Blackstone disclosed that Rodney Zemmel – a long-time Senior Partner at McKinsey, who served as the global leader of both McKinsey Digital and the firm’s AI Transformation initiatives – ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...